Skip to main content

Phoebe Starr


Authored Items
Atezolizumab Extends Disease-Free Survival in PD-L1−Positive Early-Stage NSCLC
Phoebe Starr
August 2021 Vol 14, Special Issue: Payers' Perspectives in Oncology in Conference Highlights ASCO, Lung Cancer
¹⁷⁷Lu-PSMA-617 Prolongs Survival in Patients with Metastatic Castration-Resistant Prostate Cancer
Phoebe Starr
August 2021 Vol 14, Special Issue: Payers' Perspectives in Oncology in Prostate Cancer, Conference Highlights ASCO
Adjuvant Pembrolizumab Therapy Significantly Extends Disease-Free Survival in Patients with Clear-Cell Renal-Cell Carcinoma
Phoebe Starr
August 2021 Vol 14, Special Issue: Payers' Perspectives in Oncology in Renal-Cell Carcinoma, Conference Highlights ASCO
¹⁷⁷Lu-PSMA-617 Superior to Cabazitaxel in Metastatic Prostate Cancer
Phoebe Starr
Web Exclusives in Prostate Cancer
Momelotinib, a Novel JAK Inhibitor, Makes Inroads in Intermediate- or High-Risk Myelofibrosis
Phoebe Starr
February 2021 Vol 14, Special Issue: Payers' Perspectives in Oncology
First-Line Fixed-Duration Ibrutinib plus Venetoclax Therapy Leads to Deep Remissions in Patients with Chronic Lymphocytic Leukemia
Phoebe Starr
February 2021 Vol 14, Special Issue: Payers' Perspectives in Oncology in Leukemia
Novel Target: RARA Agonist plus Azacitidine Active in Relapsed or Refractory Acute Myeloid Leukemia
Phoebe Starr
February 2021 Vol 14, Special Issue: Payers' Perspectives in Oncology in Emerging Therapies
Asciminib, First-in-Class STAMP Inhibitor, Superior to Bosutinib in Chronic-Phase CML
Phoebe Starr
February 2021 Vol 14, Special Issue: Payers' Perspectives in Oncology in Leukemia
Ruxolitinib in Graft-versus-Host Disease: Practice-Changing Results
Phoebe Starr
February 2021 Vol 14, Special Issue: Payers' Perspectives in Oncology in Graft-versus-Host Disease
Sotorasib, First-in-Class KRAS G12C Inhibitor, Hailed as “Triumph of Drug Discovery”
Phoebe Starr
Web Exclusives in ESMO 2020 Highlights
Olaparib a New Option for Men with Metastatic Prostate Cancer and BRCA Mutation
Phoebe Starr
Web Exclusives in ESMO 2020 Highlights
Nivolumab New Standard of Care in Gastroesophageal Cancers as First-Line or Adjuvant Therapy
Phoebe Starr
Web Exclusives in ESMO 2020 Highlights
COVID-Related Death Rate Tripled in Patients with Cancer versus the General Population
Phoebe Starr
Web Exclusives in COVID-19
Maintenance Avelumab New Standard of Care for Advanced Bladder Cancer
Phoebe Starr
August 2020 Vol 13, Special Issue: Payers' Perspectives in Oncology
No Survival Benefit with Surgery and Radiation Added to Systemic Therapy in Patients with Newly Diagnosed Stage IV Breast Cancer
Phoebe Starr
August 2020 Vol 13, Special Issue: Payers' Perspectives in Oncology in Breast Cancer
Cabozantinib plus Atezolizumab Combination Shows Meaningful Activity in Metastatic Prostate Cancer
Phoebe Starr
August 2020 Vol 13, Special Issue: Payers' Perspectives in Oncology in Prostate Cancer
Oral Relugolix Equals Standard ADT, Slashes Cardiac Events in Patients with Advanced Prostate Cancer
Phoebe Starr
August 2020 Vol 13, Special Issue: Payers' Perspectives in Oncology in Prostate Cancer
Durvalumab plus Chemotherapy New Standard of Care for Extensive-Stage Small-Cell Lung Cancer
Phoebe Starr
August 2020 Vol 13, Special Issue: Payers' Perspectives in Oncology in Lung Cancer
Adjuvant Atezolizumab Did Not Show Disease-Free Survival Benefit in High-Risk Urothelial Cancer
Phoebe Starr
August 2020 Vol 13, Special Issue: Payers' Perspectives in Oncology
Early Phase 2 Data Promising for Lutetium-177 PSMA-617 in Metastatic Prostate Cancer
Phoebe Starr
August 2020 Vol 13, Special Issue: Payers' Perspectives in Oncology in Prostate Cancer
Novel BCMA-Directed CAR T-Cell Therapy Had Excellent Responses in Heavily Pretreated Patients with Multiple Myeloma
Phoebe Starr
February 2020 Vol 13, Special Issue: Payers' Perspectives in Oncology in Multiple Myeloma
Zanubrutinib, Next-Generation BTK, Leads to Impressive Responses in Patients with CLL or SLL
Phoebe Starr
February 2020 Vol 13, Special Issue: Payers' Perspectives in Oncology in Leukemia
Mosunetuzumab, a Dual-Targeted Antibody, Shows Complete Remissions in Relapsed/Refractory NHL After CAR T-Cell Therapy
Phoebe Starr
February 2020 Vol 13, Special Issue: Payers' Perspectives in Oncology in Emerging Therapies
Real-World Healthcare Utilization and Costs Support Broader Use of CAR T-Cell Therapy
Phoebe Starr
February 2020 Vol 13, Special Issue: Payers' Perspectives in Oncology in Value-Based Care
Dual-Targeted CAR T-Cell Therapy Leads to Very High Response Rates in Relapsed or Refractory Multiple Myeloma
Phoebe Starr
February 2020 Vol 13, Special Issue: Payers' Perspectives in Oncology in Multiple Myeloma
Gilteritinib and CX-01 in the Treatment of Patients with Acute Myeloid Leukemia
Phoebe Starr
August 2019, Vol 12, Special Issue: Payers' Perspectives In Oncology: ASCO 2019 Highlights in Leukemia
Fixed-Duration Targeted Therapy with Venetoclax plus Obinutuzumab New Front-Line Standard for Patients with Chronic Lymphocytic Leukemia
Phoebe Starr
August 2019, Vol 12, Special Issue: Payers' Perspectives In Oncology: ASCO 2019 Highlights in Leukemia
Enfortumab Vedotin Promising Third-Line Option for Metastatic Urothelial Cancer
Phoebe Starr
August 2019, Vol 12, Special Issue: Payers' Perspectives In Oncology: ASCO 2019 Highlights in Emerging Therapies
FDA Unveils Oncology-Specific “Project Facilitate,” Expanding Access to Investigational Cancer Drugs
Phoebe Starr
August 2019, Vol 12, Special Issue: Payers' Perspectives In Oncology: ASCO 2019 Highlights in Value-Based Care
Practice-Changing Results: Olaparib Maintenance Therapy Extends Progression-Free Survival in Metastatic Pancreatic Cancer with Germline BRCA Mutation
Phoebe Starr
August 2019, Vol 12, Special Issue: Payers' Perspectives In Oncology: ASCO 2019 Highlights in Pancreatic Cancer
MONALEESA-7 Sets New Standard of Care for Premenopausal Advanced Breast Cancer: Adding CDK4/6 to Endocrine Therapy Extends Survival
Phoebe Starr
August 2019, Vol 12, Special Issue: Payers' Perspectives In Oncology: ASCO 2019 Highlights in Breast Cancer
Enzalutamide or Apalutamide Added to ADT Improves Outcomes in Hormone-Sensitive Prostate Cancer
Phoebe Starr
August 2019, Vol 12, Special Issue: Payers' Perspectives In Oncology: ASCO 2019 Highlights in Prostate Cancer
Access to Health Insurance Reduces Disparities in Cancer Care: The Case for the ACA
Phoebe Starr
August 2019, Vol 12, Special Issue: Payers' Perspectives In Oncology: ASCO 2019 Highlights in Disparities in Oncology
Combination Immune Blockade Promising in High-Grade Neuroendocrine Tumors: The DART “Basket” Clinical Trial
Phoebe Starr
August 2019, Vol 12, Special Issue: Payers' Perspectives In Oncology: ASCO 2019 Highlights in Neuroendocrine Tumors
Researchers Identify First Mutation to Explain Resistance to Venetoclax
Phoebe Starr
January/February 2019, Vol 12, Special Issue: Payers’ Perspectives in Oncology: ASH 2018 Highlights in Leukemia
Durable Responses to CAR T-Cell Therapy in B-Cell Lymphomas
Phoebe Starr
January/February 2019, Vol 12, Special Issue: Payers’ Perspectives in Oncology: ASH 2018 Highlights in Immunotherapy
Explosive Development of BCMA CAR T-Cell Therapies for Multiple Myeloma
Phoebe Starr
January/February 2019, Vol 12, Special Issue: Payers’ Perspectives in Oncology: ASH 2018 Highlights in Immunotherapy
Checkpoint Inhibitor a New Approach to Jump-Start a Waning Response to CAR T-Cell Therapy
Phoebe Starr
January/February 2019, Vol 12, Special Issue: Payers’ Perspectives in Oncology: ASH 2018 Highlights in Immunotherapy
MURANO: Venetoclax-Rituximab at Fixed Duration Beats Chemo­immunotherapy in Relapsed/Refractory CLL
Phoebe Starr
January/February 2019, Vol 12, Special Issue: Payers’ Perspectives in Oncology: ASH 2018 Highlights in Leukemia
Nelarabine Therapy Up Front Boosts Survival in T-Cell Leukemia and Lymphoma
Phoebe Starr
August 2018 Vol 11, Special Issue in Leukemia
Cost of Treating Colorectal Cancer in the United States Double That of Canada, with No Survival Benefit
Phoebe Starr
August 2018 Vol 11, Special Issue in Value-Based Care
Next-Generation Sequencing More Cost-Effective and Faster Than Single-Gene Testing
Phoebe Starr
August 2018 Vol 11, Special Issue in Value-Based Care
With Access to Care, Black Men in the United States Have Same Prostate Cancer Outcomes as White Men
Phoebe Starr
August 2018 Vol 11, Special Issue in Prostate Cancer
Ivosidenib a New Standard of Care for Relapsed or Refractory AML with IDH1 Mutation
Phoebe Starr
August 2018 Vol 11, Special Issue in Emerging Therapies
Immunotherapy Combinations "Raising the Bar"
Phoebe Starr
August 2018 Vol 11, Special Issue in Immunotherapy
Less Is More: 6 Months of Trastuzumab Treatment Equivalent to 12 Months in HER2-Positive Breast Cancer
Phoebe Starr
August 2018 Vol 11, Special Issue in Breast Cancer
Chemotherapy Can Be Spared in Many Patients with Early Breast Cancer: Devil Is in the Details
Phoebe Starr
August 2018 Vol 11, Special Issue in Breast Cancer
Abemaciclib, a New CDK4/CDK6 Inhibitor, Added to Fulvestrant Extends PFS in Advanced HR-Positive, HER2-Negative Breast Cancer
Phoebe Starr
August 2017, Vol 10, Special Issue: Payers’ Perspectives in Oncology: ASCO 2017 Highlights in Breast Cancer
Alectinib New Standard of Care for ALK-Positive Non–Small-Cell Lung Cancer
Phoebe Starr
August 2017, Vol 10, Special Issue: Payers’ Perspectives in Oncology: ASCO 2017 Highlights in Lung Cancer
Proactive Symptom Self-Reporting Extends Survival in Patients with Metastatic Cancer
Phoebe Starr
August 2017, Vol 10, Special Issue: Payers’ Perspectives in Oncology: ASCO 2017 Highlights in Value-Based Care
Checkpoint Inhibitors Show Promise in Patients with Mesothelioma
Phoebe Starr
August 2017, Vol 10, Special Issue: Payers’ Perspectives in Oncology: ASCO 2017 Highlights in Immunotherapy
Pembrolizumab Makes Inroads in Sarcoma Subtypes
Phoebe Starr
August 2017, Vol 10, Special Issue: Payers’ Perspectives in Oncology: ASCO 2017 Highlights in Immunotherapy
Novel Assay Provides 100 Times More Information Than Current Liquid Biopsies for Early Cancer Detection
Phoebe Starr
August 2017, Vol 10, Special Issue: Payers’ Perspectives in Oncology: ASCO 2017 Highlights in Emerging Therapies
Novel Drug “Home Run” for TRK Mutation–Positive Tumors
Phoebe Starr
August 2017, Vol 10, Special Issue: Payers’ Perspectives in Oncology: ASCO 2017 Highlights in Emerging Therapies
Less Is More: Low-Risk Stage III Colon Cancer Safely Treated with Only 3 Months of Adjuvant Chemotherapy
Phoebe Starr
August 2017, Vol 10, Special Issue: Payers’ Perspectives in Oncology: ASCO 2017 Highlights
CPX-351 Improves Posttransplant Survival in Older Patients with High-Risk Acute Myeloid Leukemia
Phoebe Starr
February 2017 Vol 10, Special Issue: Payers’ Perspectives In Oncology: ASH 2016 Highlights in Leukemia
Strategies to Reduce the Use of Tyrosine Kinase Inhibitors in CML
Phoebe Starr
February 2017 Vol 10, Special Issue: Payers’ Perspectives In Oncology: ASH 2016 Highlights in Leukemia
Pacritinib Shows Good Efficacy in Myelofibrosis: Will the FDA Release Hold on the Drug?
Phoebe Starr
February 2017 Vol 10, Special Issue: Payers’ Perspectives In Oncology: ASH 2016 Highlights
R-CHOP Prevails Over Dose-Adjusted EPOCH-R as Standard of Care for Diffuse Large B-Cell Lymphoma
Phoebe Starr
February 2017 Vol 10, Special Issue: Payers’ Perspectives In Oncology: ASH 2016 Highlights in Lymphoma
CAR T-Cell Therapy Succeeds in Aggressive Lymphoma
Phoebe Starr
February 2017 Vol 10, Special Issue: Payers’ Perspectives In Oncology: ASH 2016 Highlights in Emerging Therapies
Obinutuzumab Prolongs Survival in Follicular Lymphoma
Phoebe Starr
February 2017 Vol 10, Special Issue: Payers’ Perspectives In Oncology: ASH 2016 Highlights in Lymphoma
Refining the Use of CAR T-Cells in Patients with Acute Lymphoblastic Leukemia
Phoebe Starr
August 2016 Vol 9, Special Issue: Payers' Perspectives in Oncology in Leukemia
Extending Letrozole Therapy Beyond 5 Years in Early Breast Cancer Reduces Recurrence
Phoebe Starr
August 2016 Vol 9, Special Issue: Payers' Perspectives in Oncology in Breast Cancer
Combination Immunotherapy Makes Progress in Advanced Melanoma
Phoebe Starr
August 2016 Vol 9, Special Issue: Payers' Perspectives in Oncology in Melanoma
A New Paradigm Matching Targeted Therapy to Molecular Alterations Independent of Tumor Type
Phoebe Starr
August 2016 Vol 9, Special Issue: Payers' Perspectives in Oncology
Shorter Hypofractionated Therapy New Standard for Prostate Cancer
Phoebe Starr
August 2016 Vol 9, Special Issue: Payers' Perspectives in Oncology in Prostate Cancer
Biosimilar to Trastuzumab Shows Equivalent Efficacy and Safety
Phoebe Starr
August 2016 Vol 9, Special Issue: Payers' Perspectives in Oncology in Emerging Therapies
New Standard in Elderly Patients with Glioblastoma Based on Phase 3 Evidence
Phoebe Starr
August 2016 Vol 9, Special Issue: Payers' Perspectives in Oncology in Emerging Therapies
Aggressive End-of-Life Care Continues to Be Offered to Younger Patients with Cancer
Phoebe Starr
August 2016 Vol 9, Special Issue: Payers' Perspectives in Oncology
“Smart Bomb” First-in-Class Drug Rova-T Promising Novel Therapy for Small-Cell Lung Cancer
Phoebe Starr
August 2016 Vol 9, Special Issue: Payers' Perspectives in Oncology in Emerging Therapies, In the News
Checkpoint Inhibitors in Lymphoma: A New Universe
Phoebe Starr
February 2016 Vol 9, Special Issue: Payers' Perspectives in Oncology
Ibrutinib a New Standard of Care for Elderly Patients with Chronic Lymphocytic Leukemia
Phoebe Starr
February 2016 Vol 9, Special Issue: Payers' Perspectives in Oncology in Leukemia
Idelalisib Improves Survival When Added to Bendamustine plus Rituximab in Patients with CLL
Phoebe Starr
February 2016 Vol 9, Special Issue: Payers' Perspectives in Oncology in Leukemia
The Hematologic Drug Pipeline: Exciting New Treatment Options Looming
Phoebe Starr
February 2016 Vol 9, Special Issue: Payers' Perspectives in Oncology in Emerging Therapies
Midostaurin the First Targeted Therapy to Improve Survival in AML: Potentially Practice-Changing
Phoebe Starr
February 2016 Vol 9, Special Issue: Payers' Perspectives in Oncology in Emerging Therapies
Venetoclax Shows Strong Activity in CLL
Phoebe Starr
February 2016 Vol 9, Special Issue: Payers' Perspectives in Oncology in Emerging Therapies
Nivolumab Beats Docetaxel as Second-Line Therapy for Patients with NSCLC
Phoebe Starr
August 2015 Vol 8, Special Issue: Payers' Perspectives in Oncology in Emerging Therapies
Oral Nicotinamide Prevents Common Skin Cancers in High-Risk Patients, Reduces Costs
Phoebe Starr
August 2015 Vol 8, Special Issue: Payers' Perspectives in Oncology
Encouraging Results for Pembrolizumab in Head and Neck Cancer
Phoebe Starr
August 2015 Vol 8, Special Issue: Payers' Perspectives in Oncology in Emerging Therapies
Elotuzumab, First-in-Class Monoclonal Antibody Immuno­­therapy, Improves Outcomes in Patients with Multiple Myeloma
Phoebe Starr
August 2015 Vol 8, Special Issue: Payers' Perspectives in Oncology in Emerging Therapies
Genetic Abnormality Pinpointed for Intensive Therapy in Wilms Tumor
Phoebe Starr
August 2015 Vol 8, Special Issue: Payers' Perspectives in Oncology
Adding Ibrutinib to Standard Therapy Reduces Disease Progression by 80% in Previously Treated Patients with CLL
Phoebe Starr
August 2015 Vol 8, Special Issue: Payers' Perspectives in Oncology in Leukemia
Stem-Cell Transplant Safe in HIV-Related Lymphoma
Phoebe Starr
February 2015 Vol 8, Special Issue: Payers' Perspectives in Oncology in Lymphoma
Posttransplant Brentuximab: New Standard in Hodgkin Lymphoma?
Phoebe Starr
February 2015 Vol 8, Special Issue: Payers' Perspectives in Oncology in Lymphoma
Psychological Distress and Financial Burden Impact Adherence to CML Treatment
Phoebe Starr
February 2015 Vol 8, Special Issue: Payers' Perspectives in Oncology in Leukemia
ALTTO: Dual Anti-HER2 Adjuvant Therapy No Better than Trastuzumab Alone
Phoebe Starr
August 2014 Vol 7, Special Issue ASCO 2014 Payers' Perspectives in Oncology in Breast Cancer
Two Genetic Tests Can Prevent Overtreatment of Early Prostate Cancer
Phoebe Starr
August 2013 Vol 6, No 6 Special Issue
Pazopanib: First Positive Maintenance Trial in Ovarian Cancer
Phoebe Starr
August 2013 Vol 6, No 6 Special Issue in Emerging Therapies
The Role of Personalized Medicine in the Management of Patients with Breast Cancer
Phoebe Starr
January/February 2013 Vol 6, No 1 in Conference Highlights SABCS
Last modified: February 14, 2013